Insulet stock maintains Buy rating at Benchmark after recall

Insulet Corporation faces renewed investor scrutiny following a voluntary medical device correction announced on May 26, 2026, affecting approximately 7 million Omnipod insulin pods across three product lines: Omnipod 5, Omnipod DASH, and Omnipod Eros. The manufacturing defect involves potential insulin leakage caused by small tears in pod tubing, which could result in under-delivery of insulin to diabetic patients. The company identified 24 serious adverse events associated with the defect, including cases of high blood glucose levels requiring hospitalization and Diabetic Ketoacidosis (DKA), though no fatalities have been reported.

Despite the recall announcement, Benchmark initiated coverage on May 12 with a Buy rating and $250 price target, maintaining both the rating and target through the May 27 announcement. The analyst firm noted that while some second-quarter special charges appear likely, Benchmark made no change to its earnings estimates at this time. This reflects measured confidence in the company's ability to absorb the financial impact, particularly given that approximately 60% of the 7 million affected pods have already been consumed or expired, effectively limiting exposure.

The broader analyst community remains constructively positioned on Insulet. Among 25 analysts covering the stock, the consensus rating is "Strong Buy," based on 18 strong buy ratings and two moderate buy ratings. The consensus mean price target stands near $250, implying 62% upside potential from current levels near $142.30. Goldman Sachs, while reducing its price target from $237 to $205 on May 27, cited competition concerns and quality challenges but maintained its Buy rating. The analyst noted that medical technology sector headwinds and manufacturing issues are creating near-term pressure, yet the long-term business case remains intact.

Insulet's operational fundamentals support the analyst optimism despite the stock's 53% decline over the past six months. The company maintains a robust 71% gross profit margin and has remained profitable over the trailing twelve months. InvestingPro analysis suggests the stock is undervalued at current levels, and 10 analysts have recently revised their earnings estimates upward for the upcoming period. The manufacturing issue appears to be contained; management identified the root cause and implemented corrective actions including additional in-process monitoring and quality controls designed to detect cannula tears before products reach patients. This proactive remediation effort, combined with the limited financial exposure from already-consumed or expired pods, appears to have reinforced analyst conviction that the recall, while operationally and reputationally damaging in the near term, does not fundamentally impair Insulet's medium-to-long-term investment thesis.